



US005756349A

United States Patent [19]

[11] Patent Number: 5,756,349

Lin

[45] Date of Patent: May 26, 1998

- [54] PRODUCTION OF ERYTHROPOIETIN
- [75] Inventor: Fu-Kuen Lin, Thousand Oaks, Calif.
- [73] Assignee: Amgen Inc., Thousand Oaks, Calif.
- [21] Appl. No.: 468,369
- [22] Filed: Jun. 6, 1995

- 33 48 298 C2 11/1983 Germany .
- 2085887 5/1982 United Kingdom .
- 83/04053 11/1983 WIPO .
- 85/01961 5/1985 WIPO .
- 85/03079 7/1985 WIPO .
- 85/04419 10/1985 WIPO .
- 86/03520 6/1986 WIPO .

OTHER PUBLICATIONS

- Abraham et al., "Nucleotide Sequence of a Bovine Clone Encoding the Angiogenic Protein, Basic Fibroblast Growth Factor." *Science*, 233, 545-548 (Aug. 1, 1986).
- Adamson, "The Polycythemia: Diagnosis and Treatment." *Hosp. Practice*, 18(12), 49-57 (Dec. 1983).
- Aebi et al., "Sequence Requirements for Splicing of Higher Eukaryotic Nuclear Pre-mRNA." *Cell*, 47, 555-565 (Nov. 21, 1986).
- Agarwal et al., "A General Method for Detection and Characterization of an mRNA using an Oligonucleotide Probe." *J. Biol. Chem.*, 256, 1023-1028 (Jan. 25, 1981).
- Anderson et al., "Isolation of a genomic clone for bovine pancreatic trypsin inhibitor by using a unique-sequence synthetic DNA probe." *P.N.A.S. (USA)*, 80, 6838-6842 (Nov. 1983).
- Antonsson et al., "Posttranslational Modifications of Fibromodulin." *J. Biol. Chem.*, 266(25), 16859-16861 (1991).
- Baciu et al., "Erythropoietin Interaction with the Mature Red Cell Membrane." *Ann. N.Y. Acad. Sci.*, 414, 66-72 (1983).
- Baron et al., "Antibodies against the Chemically Synthesized Genome-Linked Protein of Poliovirus React with Native Virus-Specific Proteins." *Cell*, 28, 395-404 (Feb. 1982).

Related U.S. Application Data

- [63] Continuation of Ser. No. 113,179, Oct. 23, 1987, Pat. No. 5,441,868, which is a continuation of Ser. No. 675,298, Nov. 30, 1984, Pat. No. 4,703,008, which is a continuation-in-part of Ser. No. 561,024, Dec. 13, 1983, abandoned, which is a continuation-in-part of Ser. No. 582,185, Feb. 21, 1984, abandoned, which is a continuation-in-part of Ser. No. 655,841, Sep. 28, 1984, abandoned.

- [51] Int. Cl.⁶ C12N 15/00
- [52] U.S. Cl. 435/325; 435/358; 435/365
- [58] Field of Search 435/69.1, 69.4, 435/240.2, 240.22, 325, 358, 365

References Cited

U.S. PATENT DOCUMENTS

- 3,033,753 5/1962 White et al. 530/395
- 3,865,801 2/1975 Chiba et al. 530/397
- 4,237,224 12/1980 Cohen et al. 435/69.1
- 4,254,095 3/1981 Fisher et al. 436/513
- 4,264,731 4/1981 Shine 435/91.41
- 4,273,875 6/1981 Manis 435/91.4
- 4,293,652 10/1981 Cohen 435/172.3
- 4,303,650 12/1981 Takezawa et al. 530/397
- 4,338,397 7/1982 Gilbert et al. 435/69.1
- 4,358,535 11/1982 Falkow et al. 435/5
- 4,377,513 3/1983 Sugimoto et al. 530/395
- 4,394,443 7/1983 Weissman et al. 435/6
- 4,397,840 8/1983 Takezawa et al. 530/399
- 4,399,216 8/1983 Axel et al. 435/6
- 4,411,994 10/1983 Gilbert et al. 435/69.7
- 4,442,205 4/1984 Hamer et al. 435/69.3
- 4,465,624 8/1984 Chiba et al. 530/395
- 4,468,464 8/1984 Cohen et al. 435/320.1
- 4,503,151 3/1985 Paddock 435/69.1
- 4,558,005 12/1985 Goldwasser et al. 435/7.92
- 4,558,006 12/1985 Egrie 435/7.94
- 4,568,448 2/1986 Lee-Huang 530/397
- 4,667,016 5/1987 Lai et al. 530/397
- 4,677,195 6/1987 Hewick et al. 530/397
- 4,695,542 9/1987 Yokata et al. 435/69.4
- 4,703,008 10/1987 Lin 435/240.2
- 4,710,473 12/1987 Morris 435/320.1
- 4,757,006 7/1988 Toole et al. 435/69.6

FOREIGN PATENT DOCUMENTS

- 0070685 1/1983 European Pat. Off. .
- 0070687 1/1983 European Pat. Off. .
- 0077670 4/1983 European Pat. Off. .
- 0093619 11/1983 European Pat. Off. .
- 0116446 8/1984 European Pat. Off. .
- 0117058 8/1984 European Pat. Off. .
- 0117059 8/1984 European Pat. Off. .
- 0117060 8/1984 European Pat. Off. .
- 0123294 10/1984 European Pat. Off. .
- 0136490 4/1985 European Pat. Off. .
- 33 16 297 A1 11/1983 Germany .

(List continued on next page.)

Primary Examiner—James Martinell
Attorney, Agent, or Firm—Marshall, O'Toole, Gerstein, Murray & Borun

[57] ABSTRACT

Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin ("EPO") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Illustratively, genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequence of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Upon isolation from culture media or cellular lysates or fragments, products of expression of the DNA sequences display, e.g., the immunological properties and in vitro and in vivo biological activities of EPO of human or monkey species origins. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of EPO. Also disclosed are improved methods for the detection of specific single stranded polynucleotides in a heterologous cellular or viral sample prepared from, e.g., DNA present in a plasmid or viralborne cDNA or genomic DNA "library".

7 Claims, 27 Drawing Sheets